Choline acetyltransferase activity and striatal dopamine receptors in Parkinson's disease in relation to cognitive impairment

被引：0
作者：
Abdou W.A. [1 ]
Aveline C. [1 ]
Bonnet F. [1 ]
机构：
[1] Départment d’Anesthésie-Réanimation Chirurgicale, Hôpital TP
来源：
Acta Neuropathologica | 2001年 / 102卷 / 2期
关键词：
Choline acetyltransferase; Cognitive impairment; Dopamine receptor; Lewy body; Parkinson's disease;
D O I：
10.1007/s004010100372
中图分类号：
学科分类号：
摘要：
Brain tissue from 44 patients with Parkinson's disease (PD) and 36 age-matched controls was examined for choline acetyltransferase (ChAT) activity, and for densities of D1 and D2 dopamine receptors. Brain samples were examined for Alzheimer' disease (AD) type changes and for Lewy bodies (LBs), and for apolipoprotein E genotype. Patients were evaluated for the stage of cognitive impairment using Reisberg's global deterioration scale. ChAT activity in PD was reduced in all brain areas examined, being 51% of the control mean in the hippocampus (P<0.001), 57% in the prefrontal cortex (P< 0.001) and 64% in the temporal cortex (P<0.001). The number of LBs had a significant negative correlation with ChAT activity in both prefrontal (r=-0.33, P<0.05) and temporal cortex (r=-0.32, P<0.05). The reduction in ChAT activity in the prefrontal cortex had a significant negative correlation (r=-0.38, P=0.012) with the extent of cognitive impairment. When the CERAD class 'C' was excluded, cognitive impairment correlated significantly with both prefrontal ChAT activity (r=-0.52, P=0.0051) and the density of D1 dopamine receptors in the caudate nucleus (r=-0.40, P=0.037). The number of D1 and D2 dopamine receptors was reduced in both caudate nucleus and putamen in PD patients without neuroleptics as compared to controls. An increased D2 receptor number was found in the caudate nucleus and putamen in PD patients treated with neuroleptics. The present study showed that cognitive decline in PD is associated with reduced ChAT activity in the prefrontal cortex and the D1 dopamine receptor number in the caudate nucleus, even in the absence of AD-type pathology.
引用
收藏
页码：160 / 166
页数：6
相关论文
共 53 条
  • [1] Antonini A., Schwarz J., Oertel W.H., Beer H.F., Madeja U.D., Leenders K., [<sup>11</sup>C]Raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: Influence of L-dopa and lisuride therapy on striatal dopamine D2 receptors, Neurology, 44, pp. 1325-1329, (1994)
  • [2] Brooks D.J., Salmon E.P., Mathias C.J., Quinn N., Leenders K.L., Bannister R., Marsden C.D., Frackowiak R.S., The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET, Brain, 113, pp. 1539-1552, (1990)
  • [3] Brooks D.J., Ibanez V., Sawle G.V., Playford E.D., Quinn N., Mathias C.J., Lees A.J., Marsden C.D., Bannister R., Frackowiak R.S.J., Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration and progressive supranuclear palsy, measured with <sup>11</sup>C-raclopride and positron emission tomography, Ann Neurol, 31, pp. 184-192, (1992)
  • [4] Burkhardt C.R., Filley C.M., Kleinschmidt-DeMasters B.K., de la Monte S., Norenberg M.D., Schneck S.A., Diffuse Lewy body disease and progressive dementia, Neurology, 38, pp. 1520-1528, (1988)
  • [5] Davies P., Maloney A.J.F., Selective loss of central cholinergic neurons in Alzheimer's disease, Lancet, 2, (1976)
  • [6] Dickson D.W., Davies P., Mayeux R., Crystal H., Horoupian D.S., Thompson A., Goldman J.E., Diffuse Lewy body disease. Neuropathological and biochemical studies of six patients, Acta Neuropathol (Berl), 75, pp. 8-15, (1987)
  • [7] Dubois B., Ruberg M., Javoy-Agid F., Ploska A., Agid Y., A subcortico-cortical cholinergic system is affected in Parkinson's disease, Brain Res, 288, pp. 213-218, (1983)
  • [8] Dubois B., Pillon B., Malapani C., Deweer B., Verin M., Partiaud A., Defontaines B., Sirigu A., Texeira C., Agid Y., Subcortical dementia and Parkinson's disease: What are the cognitive functions of the basal ganglia?, Mental Dysfunction in Parkinson's Disease, 1, pp. 195-210, (1994)
  • [9] Emi M., Wu L.L., Robertson M.A., Myers R.L., Hegele R.A., Williams R.L., White R., Landouel J.-M., Genotyping and sequence analysis of apolipoprotein E isoforms, Genomics, 3, pp. 373-379, (1988)
  • [10] Farde L., Gustavsson J.P., Jonsson E., D2 dopamine receptors and personality traits, Nature, 13, 385, (1997)
123456